Novartis Provides Update on Phase III CANOPY-A Study Evaluating Canakinumab as Adjuvant Treatment in Non-small Cell Lung Cancer

Novartis announced that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab , an inhibitor of interleukin-1beta, in adult patients with stages II-IIIA and IIIB completely resected NSCLC did not meet its primary endpoint of disease-free survival versus placebo